Deamorphization of spray-dried formulations via spray-blending

a technology of spray-dried formulations and spray-blending, which is applied in the direction of drug compositions, biocide, anti-inflammatory agents, etc., can solve the problems of micronized drug particle coarsening, thermodynamic instability of amorphous domains, and undesirable presence of crystalline micronized drugs for inhalation, so as to limit the content of amorphous drugs

Pending Publication Date: 2015-12-31
NOVARTIS AG
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention relates to methods for producing dry powders with specific properties by spray-drying them. By doing this, they can have their own unique characteristics that are retained during storage without losing any of its original value or causing problems such as sedimentation.

Problems solved by technology

The technical problem addressed in this patent text relates to controlling the properties of crystalline forms of active agents used in medications like asthmatics and COPD therapy. These drugs exhibit different crystal structures due to their unique physicochemistry and crystal structure. However, current methods for making crystalline forms involve expensive processes involving multiple steps, leading to potential impurity issues during production. Therefore, there is a need for improved methods for preparing crystalline forms of active agents for use in medicine.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Deamorphization of spray-dried formulations via spray-blending
  • Deamorphization of spray-dried formulations via spray-blending
  • Deamorphization of spray-dried formulations via spray-blending

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of Spray-Blended Dry Powder Formulations of Indacaterol Maleate and Indacaterol Maleate+Mometasone Furoate

[0214]In this Example, dry powder formulations of the invention containing indacaterol maleate were prepared by a spray-blending process. This includes a formulation comprising a fixed dose combination of indacaterol maleate and mometasone furoate.

[0215]Five spray-blended formulations (see Tables 3 and 4) were prepared and spray-dried on a Niro PS-1 scale spray-drier, equipped with a multi-headed HYDRA™ atomizer. The HYDRA™ atomizer (FIG. 3) contains five twin fluid nozzles (see FIG. 3A), each of which is controlled by an independent liquid feed line as shown schematically in FIG. 3B. A common gas line was used to supply atomization gas (compressed air) to all nozzles. The nozzles are oriented to minimize interaction of the spray plumes during drying. For the five lots detailed below, only three of the five spray nozzles were utilized (Feedlines A, B, C). The compositio

example 2

Preparation of Spray-Blended Dry Powder Formulations of Indacaterol Maleate and Indacaterol Maleate+Mometasone Furoate from an Emulsion-Based Feedstock

[0222]In this Example, more detail is provided on the preparation of the feedstocks used in Example 1. The dry powder formulations of the invention containing indacaterol maleate were prepared and dry powder formulations of the invention containing indacaterol maleate and mometasone furoate were prepared from an emulsion-based feedstock that was prepared in accordance with the method described in United States patent specification U.S. Pat. No. 6,565,885. In this process, crystalline micronized indacaterol maleate is dispersed in the continuous phase of an oil-in-water emulsion. The process resulted in crystalline indacaterol particles coated with a porous layer of hydrophobic excipient. The morphology of the particles was confirmed by scanning electron microscopy (data not shown).

[0223]Accordingly, distearoylphosphatidylcholine (DSPC) a

example 3

Measurement of the Physical Properties of Spray-Blended Dry Powder Formulations of Indacaterol Maleate and Indacaterol Maleate+Mometasone Furoate

[0230]In this Example certain physicochemical properties of the spray-blended dry powder formulations in Example 1 were measured, namely primary particle size, tapped density and water content.

[0231]FIGS. 7A-7E are photomicrographs of spray-blended powders of embodiments of the present invention, the powders comprising indacaterol. The powders were formulated according to Table 3, and FIGS. 7A-E correspond in order to the Lot I through Lot V. The powders exhibit the hollow, porous morphology characteristic of the emulsion-based spray drying process. There is no evidence of different types of particles in the spray-blended formulations of FIGS. 7A-E.

[0232]Table 6 presents the physical properties measured for those formulations.

TABLE 6Physical properties of spray-blended dry powder formulations ofindacaterol maleate and indacaterol maleate + mom

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Lengthaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to view more

Abstract

Dry powder formulations for inhalation and their use in the treatment diseases and conditions. The formulation contains a uniform blend of a first spray-dried powder and a second spray-dried powder. The first spray-dried powder contains spray-dried particles of a therapeutically active ingredient dispersed in a pharmaceutically acceptable hydrophobic excipient. The second spray-dried powder contains spray-dried particles formed from a pharmaceutically acceptable hydrophobic excipient but are substantially free of any therapeutically active ingredient. The active ingredient in the first spray-dried powder is loaded sufficiently high to compensate for the second spray-dried powder being substantially free of any active ingredient. A process for preparing such formulations is also described.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner NOVARTIS AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products